Cancer Care's AIDS Pain Booklet Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 1
Volume 6
Issue 1

NEW YORK--Cancer Care, Inc. has a new booklet, "Pain in HIV/AIDS: Control Your Pain So It Doesn't Control You," that provides information about pain management to people with HIV, to help them advocate for themselves and receive

NEW YORK--Cancer Care, Inc. has a new booklet, "Pain in HIV/AIDS:Control Your Pain So It Doesn't Control You," that provides informationabout pain management to people with HIV, to help them advocate for themselvesand receive effective pain management. For free copies, call Cancer Careat 212-221-3300 or toll-free at 1-800-813-4673.

Articles in this issue
New Board to Deal With Cancer Policy Issues
MoAb Shows Positive Results in Lymphoma Patients
Prostate Cancer Gene Location Narrowed to Chromosome 1 Arm
New BCG Bladder Cancer Indication Gets Panel Nod
Panel Advises FDA To OK Letrozole for Advanced Breast Cancer
Limited Diagnostic Testing After Breast Cancer Treatment Urged
Pressures of Managed Care Spur Interest in Clinical Guidelines
Baltimore Will Head New Effort To Develop a Vaccine for HIV
Epidemiologist Challenges Tamoxifen, Second Cancer Link
Cancer Care's AIDS Pain Booklet Available
AIDS Center Director Offers Advice on Selecting a Physician
Good Outcomes Seen With Hyperfractionated Conformal RT
Goals of Planned National Pain Research Consortium Outlined
New Evidence Supports Screening in Younger Women
Interferon Improves Survival in CML
Recent Videos
4 experts in this video
4 experts in this video
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Related Content
After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.

mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer

Roman Fabbricatore
August 22nd 2025
Article

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.

Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Oxaliplatin Elicits Improved Survival in Select Patients with Stage III CRC

Roman Fabbricatore
August 22nd 2025
Article

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Multivariate analysis showed that females had an increased risk of progressive disease vs males.

Serplulimab plus Chemotherapy Improves OS and PFS in Elderly ES-SCLC

Tim Cortese
August 22nd 2025
Article

The biomarker NLR may not be suitable for prognosis prediction in elderly patients with small cell lung cancer, according to this real-world study.

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Dordaviprone Offers “Exciting” Option for Diffuse Midline Glioma Population

Roman Fabbricatore
August 21st 2025
Article

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.